Pfizer, a United States-based pharmaceutical company, announced on Friday the approval of its innovative migraine therapy in China for the acute treatment of migraines in adults, whether with or without warning signs.

Pfizer claims that this therapy, the world's first and only oral drug for this purpose, can block key pathways associated with the pathogenesis of migraines.

The company asserts that it can swiftly and continuously alleviate headaches and related symptoms.

This treatment, currently the sole one globally approved in both the United States and the European Union, has received recommendations in migraine treatment guidelines across the US, Europe, and China.

Pfizer anticipates that this approval will provide a new and valuable treatment option for Chinese patients grappling with migraines.

Jean-Christophe Pointeau, senior vice-president of Pfizer and president of Pfizer China, said, "Neuroscience is a key focus for Pfizer to delve into and expand. The approval of this new drug in China is expected to help Chinese migraine patients enhance their quality of life. It is also a significant manifestation of the company's commitment to establishing a presence in the Chinese market and serving Chinese patients."

Migraines are a prevalent and debilitating condition often accompanied by complications such as anxiety, depression, cerebrovascular diseases, and sleep disorders, imposing a substantial disease burden. Experts estimate the prevalence of the disease in China to be around 9 percent.